WESPAC Advisors’s West Pharmaceutical WST Stock Holding History

WESPAC Advisors’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,894	Closed	-$537K	–	187
2020 Q4	$537K	Buy	+1,894	New	+$531K	0.41%	80

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

WESPAC Advisors's WST Position: Q1 2021 in Review

WESPAC Advisors sold out of West Pharmaceutical (WST) in Q1 2021, closing a stake of 1,894 shares — an estimated $537K sold.

WESPAC Advisors first reported a position in WST in Q4 2020 and held it in 1 quarter. The position peaked at $537K in Q4 2020. 590 funds tracked by Wall St. Rank hold WST as of Q1 2021.

WESPAC Advisors reported no remaining West Pharmaceutical position as of Q1 2021 after selling out during the quarter.
WESPAC Advisors sold 1,894 West Pharmaceutical shares in Q1 2021, an estimated $537K.
WESPAC Advisors first reported a position in West Pharmaceutical in Q4 2020 and held it in 1 quarter.
WESPAC Advisors's West Pharmaceutical position peaked at $537K in Q4 2020.
590 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2021.

Based on WESPAC Advisors's 13F filing for Q1 2021, filed 10 May 2021.